Sanofi - Aventis Groupe: Data from two Phase 3 studies demon

Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH's plenary and late-breaking

Related Keywords

Paris , France General , France , United States , America , American , Eva Schaefer Jansen , Arnaud Delepine , Felix Lauscher , Nathalie Pham , Dietmar Berger , Sally Bain , American Society Of Hematology , Global Head Of Development , Alnylam Pharmaceutical Inc , American Society , Late Breaking Abstract Session , Plenary Scientific Session , Global Head , Alnylam Pharmaceutical , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Sanofi , Eventis , Roupe , Data , Rom , Hase , Studies , Emonstrating , Fitusiran , Ignificantly , Educed , Leeds , People , Hemophilia , Without , Inhibitors , Were , Featured , Plenary , Gate , Breaking , Session ,